HRP20170874T4 - Formulacija kontrastnog medija i odgovarajući postupak dobivanja - Google Patents

Formulacija kontrastnog medija i odgovarajući postupak dobivanja Download PDF

Info

Publication number
HRP20170874T4
HRP20170874T4 HRP20170874TT HRP20170874T HRP20170874T4 HR P20170874 T4 HRP20170874 T4 HR P20170874T4 HR P20170874T T HRP20170874T T HR P20170874TT HR P20170874 T HRP20170874 T HR P20170874T HR P20170874 T4 HRP20170874 T4 HR P20170874T4
Authority
HR
Croatia
Prior art keywords
complex
preparation
mol
formula
ch2oh
Prior art date
Application number
HRP20170874TT
Other languages
English (en)
Croatian (hr)
Inventor
Christelle Medina
Monique SABATOU
Anne PETIT
Marc Port
Original Assignee
Guerbet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48856855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20170874(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Guerbet filed Critical Guerbet
Publication of HRP20170874T1 publication Critical patent/HRP20170874T1/hr
Publication of HRP20170874T4 publication Critical patent/HRP20170874T4/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
HRP20170874TT 2013-04-26 2014-04-28 Formulacija kontrastnog medija i odgovarajući postupak dobivanja HRP20170874T4 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1353883 2013-04-26
EP14723750.7A EP2988756B2 (fr) 2013-04-26 2014-04-28 Formulation de produit de contraste et son procede de preparation associe
PCT/EP2014/058617 WO2014174120A1 (fr) 2013-04-26 2014-04-28 Formulation de produit de contraste et son procede de preparation associe

Publications (2)

Publication Number Publication Date
HRP20170874T1 HRP20170874T1 (hr) 2017-09-22
HRP20170874T4 true HRP20170874T4 (hr) 2022-09-02

Family

ID=48856855

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170874TT HRP20170874T4 (hr) 2013-04-26 2014-04-28 Formulacija kontrastnog medija i odgovarajući postupak dobivanja

Country Status (14)

Country Link
US (1) US10918743B2 (enExample)
EP (1) EP2988756B2 (enExample)
JP (1) JP6608805B2 (enExample)
KR (1) KR102231121B1 (enExample)
CN (2) CN105142649A (enExample)
BR (1) BR112015026473B1 (enExample)
CA (1) CA2909919C (enExample)
DK (1) DK2988756T4 (enExample)
ES (1) ES2626582T5 (enExample)
HR (1) HRP20170874T4 (enExample)
HU (1) HUE033219T2 (enExample)
PL (1) PL2988756T5 (enExample)
PT (1) PT2988756T (enExample)
WO (1) WO2014174120A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
FR3039767B1 (fr) 2015-08-04 2017-09-08 Guerbet Sa Composition destinee a vectoriser un agent anticancereux
GB201610738D0 (en) 2016-06-20 2016-08-03 Ge Healthcare As Chelate compounds
KR102464647B1 (ko) 2016-11-28 2022-11-08 바이엘 파마 악티엔게젤샤프트 자기 공명 영상화에 사용하기 위한 높은 이완도 가돌리늄 킬레이트 화합물
CA3048104A1 (en) 2016-12-21 2018-06-28 Ge Healthcare As Tetraazabicyclo-macrocycle based manganese chelate compounds suitable as mri imaging agents
CN111712477B (zh) 2017-12-20 2024-02-02 通用电气公司 阴离子螯合物化合物
JP7558146B2 (ja) 2018-08-06 2024-09-30 ブラッコ・イメージング・ソシエタ・ペル・アチオニ Ｐｃｔａベースの造影剤
AU2019382881B2 (en) 2018-11-23 2025-06-12 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof
US11426470B2 (en) 2019-01-17 2022-08-30 Guerbet Complex of gadolinium and a chelating ligand derived of a diastereoisomerically enriched PCTA and synthesis method
FR3091872B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de synthese
FR3091873B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
US11370804B2 (en) 2019-01-17 2022-06-28 Guerbet Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
KR20230041007A (ko) * 2020-07-17 2023-03-23 게르브 Pcta로부터 유도된 킬레이팅 리간드의 제조 방법
US12409239B2 (en) 2021-06-25 2025-09-09 Beacon Mri Ltd Particles for use in hyperpolarization

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
AU608759B2 (en) 1986-08-04 1991-04-18 Amersham Health Salutar Inc NMR imaging with paramagnetic polyvalents metal salts of poly-(acid-alkylene-amido)-alkanes
DE3640708C2 (de) 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
DE3854717T3 (de) 1987-06-30 1999-04-15 Mallinckrodt, Inc. (N.D.Ges.Des Staates Delaware), St. Louis, Mo. Verfahren zur erhöhung der sicherheit von metall-ligandchelaten als röntgenstrahlen-kontrastmittel.
US5334371A (en) 1988-07-20 1994-08-02 Schering Aktiengesellschaft Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI
DE4001655A1 (de) 1990-01-18 1991-07-25 Schering Ag 6-ring enthaltende makrocyclische tetraaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
GB9001245D0 (en) * 1990-01-19 1990-03-21 Salutar Inc Compounds
US7385041B2 (en) 1990-04-25 2008-06-10 Bracco International B.V. Dual functioning excipient for metal chelate contrast agents
CA2039399C (en) * 1990-04-25 2000-09-05 C. Allen Chang Dual functioning excipient for metal chelate contrast agents
DE4115789A1 (de) 1991-05-10 1992-11-12 Schering Ag Makrocyclische polymer-komplexbildner, deren komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
ZA929575B (en) 1991-12-10 1994-06-10 Dow Chemical Co Bicyclopolyazamacrocyclocarboxyclic acid complexes,their conjugates,processes for their preparation,and use as contrast agents
US5582814A (en) 1994-04-15 1996-12-10 Metasyn, Inc. 1-(p-n-butylbenzyl) DTPA for magnetic resonance imaging
DE19719033C1 (de) 1997-04-29 1999-01-28 Schering Ag Ionenpaare, Verfahren zu ihrer Herstellung und ihre Verwendung als Kontrastmittel
FR2794744B1 (fr) 1999-06-09 2001-09-21 Guerbet Sa Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
US6559330B1 (en) 1999-09-09 2003-05-06 Schering Aktiengesellschaft Calcium complex of [[(4r)-4-[bis{carboxy-.kappa.o)methyl]amino-.kappa.n]-6,9-bis[(carboxy.kappa.o)methyl]-1-[(4,4-diphenylcyclohexyl)oxy]-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecan-11-ylic-acid-.kappa.n6,.kappa.n9,.kappa.011]1-oxidato(6-)]-, hexahydrogen, its salts, pharmaceutical agents that contain these complexes, their use in treatment and as additives in diagnosis, as well as processes for the production of the complexes and agents
FR2891830B1 (fr) 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
US20090208421A1 (en) * 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
FR2927539B1 (fr) * 2008-02-19 2010-07-30 Guerbet Sa Procede de preparation d'une formulation pharmaceutique d'agents de contraste.
NO331773B1 (no) 2009-12-18 2012-03-26 Ge Healthcare As Mangankelater, sammensetninger omfattende slike og anvendelse av disse som kontrastmidler for magnettomografi (MR)
EP2554167A1 (en) * 2011-08-02 2013-02-06 Bracco Imaging S.p.A New use of l-histidine and derivatives thereof

Also Published As

Publication number Publication date
KR20160002821A (ko) 2016-01-08
PL2988756T5 (pl) 2022-09-26
BR112015026473A2 (pt) 2017-07-25
US10918743B2 (en) 2021-02-16
CN116173247A (zh) 2023-05-30
BR112015026473B1 (pt) 2020-12-01
EP2988756B1 (fr) 2017-03-08
EP2988756B2 (fr) 2022-05-18
JP2016521275A (ja) 2016-07-21
KR102231121B1 (ko) 2021-03-23
HRP20170874T1 (hr) 2017-09-22
CA2909919C (fr) 2022-07-12
DK2988756T4 (da) 2022-08-08
CN105142649A (zh) 2015-12-09
WO2014174120A1 (fr) 2014-10-30
US20160101196A1 (en) 2016-04-14
DK2988756T3 (en) 2017-06-26
JP6608805B2 (ja) 2019-11-20
PT2988756T (pt) 2017-05-08
CA2909919A1 (fr) 2014-10-30
HUE033219T2 (en) 2017-11-28
PL2988756T3 (pl) 2017-08-31
EP2988756A1 (fr) 2016-03-02
ES2626582T5 (es) 2022-10-07
ES2626582T3 (es) 2017-07-25

Similar Documents

Publication Publication Date Title
HRP20170874T4 (hr) Formulacija kontrastnog medija i odgovarajući postupak dobivanja
JP2016521275A5 (enExample)
Zhou et al. Fluorine-18-labeled Gd3+/Yb3+/Er3+ co-doped NaYF4 nanophosphors for multimodality PET/MR/UCL imaging
Krasilnikova et al. Prospects of molybdenum and rhenium octahedral cluster complexes as X-ray contrast agents
HRP20161312T2 (hr) Postupak za pripravu farmaceutske formulacije kontrastnih sredstava
HRP20170411T1 (hr) Amido spirocilični amidni i sulfonamidni derivati
JP2012532868A5 (enExample)
RU2017116217A (ru) Составы металлических комплексов
WO2017105565A3 (en) Compositions for therapeutics, targeted pet imaging and methods of their use
EA201700258A3 (ru) Раствор для очищения толстой кишки, композиция для очищения толстой кишки (варианты), набор (варианты), композиция для смешивания с водой, способ очищения толстой кишки и его использование
Shu et al. Metallic artifacts-free spectral computed tomography angiography based on renal clearable bismuth chelate
AU2025226747A1 (en) Formulation of contrast media and process of preparation thereof
WO2016163727A3 (ko) 황화수소 검출용 방사성 프로브
WO2010051196A8 (en) Novel substituted azabenzoxazoles
Bauerle et al. Monitoring molecular, functional and morphologic aspects of bone metastases using non-invasive imaging
MX356212B (es) Composciones acuosas estabilizadas de agentes de bloqueo neuromuscular.
CN103463647B (zh) 基于萘啶酰胺为识别位点的响应型核磁共振造影剂及其制备方法
JP6557442B1 (ja) 皮膚外用組成物
JP5088854B2 (ja) 拡散強調画像撮影のための造影用組成物
Philippova et al. Modified perfluorocarbon nanoparticles for dual-modal magnetic resonance imaging
CN104138604A (zh) 一种用CdTe和纳米铁合成磁共振成像造影剂的方法
RU2013147022A (ru) Соединения для применения визуализации, диагностики и/или лечения заболеваний центральной нервной системы
BR112021007707B1 (pt) Formulação farmacêutica líquida, e seu processo de preparação
Cointry et al. Z-scoring of pQCT-assessed, reference distribution/quality curves in the human tibia to evaluate the efficiency of bone mechanostat
Sun et al. Diagnostic value of electron beam tomography in the evaluation of complex congenital coarctation of aorta and interruption of aorta arch.